Abstract
Treatment of infections by Pseudomonas aeruginosa forming biofilms after antimicrobial testing on planktonic bacteria can result in substantial failure. Therefore, we offer a robust and simple experimental platform to test the impact of antimicrobials on biofilms. Antibiotic response patterns varied uniquely within biofilm formation capacity and minimal biofilm eradication concentrations (MBECs) has a significantly better discriminatory power than minimum inhibitory concentrations (MICs) to differentiate the overall efficiency of antibiotics to eradicate biofilm. Our resazurin-based 96-well-plate platform is able to emulate bacterial responses to antibiotics under biofilm conditions in a fast, simple, and cost-effective screening method adaptable to automation, and warrants trials in the clinic.
Highlights
The properties of bacteria in biofilms differ from those of planktonic bacteria [1, 2], and bacteria in biofilms have extreme tolerance to immune responses and antimicrobial therapy [3, 4]
While the new assay has proven to present an effective model of biofilm formation, in this article we describe its reproducibility and applicability for rapid antibiotic susceptibility testing of P. aeruginosa biofilms in a clinical laboratory setting
We examined which test types (MIC vs. Minimal biofilm eradication concentrations (MBEC)) were more successful in allowing concentration to be used to distinguish between biofilm formations using ordinal logistic mixed effects regression
Summary
The properties of bacteria in biofilms differ from those of planktonic bacteria [1, 2], and bacteria in biofilms have extreme tolerance to immune responses and antimicrobial therapy [3, 4]. Despite the negative impact of biofilms, to our knowledge, no treatment that directly targets bacteria in biofilms has yet been developed [1, 5]. Clinical treatments with antibiotics are usually determined from minimum inhibitory concentrations (MICs) for planktonic bacteria, and, as a result, patients may suffer from persistent. Patients with chronic infections treated with antibiotic regimens based on biofilm susceptibility-testing have better clinical outcomes than those treated with regimens based on methods measuring susceptibility to planktonic bacteria [5, 9]. We developed a simplified antibiotic susceptibility assay based on a standardized model to quantify viable cells in biofilms of Acinetobacter baumannii [10, 11]. The results clearly demonstrated the significant discriminatory power of the assay (MBEC)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of clinical microbiology and antimicrobials
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
